Hyperkalaemia potassium-sparing diuretics

Potassium supplements, potassium sparing diuretics. Hyperkalaemia. 

In combination with potassium-sparing diuretics severe hyperkalaemia may occur. The elimination of lithium is prolonged. Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive effect of ACE inhibitors. 

ALISKIREN POTASSIUM-SPARING DIURETICS AND ALDOSTERONE ANTAGONISTS Risk of hyperkalaemia Additive effect Monitor serum potassium every week until stable, then every 3-6 months... 

AMIODARONE POTASSIUM-SPARING DIURETICS Risk of T levels of eplerenone with amiodarone risk of hyperkalaemia directly related to serum levels Calcium channel blockers inhibit CYP3A4-mediated metabolism of eplerenone Restrict dose of eplerenone to 25mg/day. Monitor serum potassium concentrations closely watch for hyperkalaemia... 

POTASSIUM-SPARING DIURETICS ANALGESICS-NSAIDs Risk of hyperkalaemia with NSAIDs Renal insufficiency caused by NSAIDs can exacerbate potassium retention by these diuretics Monitor renal function and potassium closely... 

POTASSIUM-SPARING DIURETICS MACROUDES -ERYTHROMYCIN T eplerenone results in an T risk of hypotension and hyperkalaemia Eplerenone is primarily metabolized by CYP3A4 there are no active metabolites. Erythromydn moderately inhibits CYP3A4, leading to T levels of eplerenone Dosage should not exceed 25 mg daily... 

POTASSIUM-SPARING DIURETICS TRIMETHOPRIM Risk of hyperkalaemia when trimethoprim is co-administered with eplerenone Additive effect Monitor potassium levels closely... 

POTASSIUM-SPARING DIURETICS CICLOSPORIN t risk of hyperkalaemia Additive effect >- For signs and symptoms of hyperkalaemia, see Clinical Features of Some Adverse Drug Interactions, Hyperkalaemia... 

POTASSIUM-SPARING DIURETICS PROGESTOGENS t risk of hyperkalaemia Drospirenone (component of the Yasmin brand of combined contraceptive pill) is a progestogen derived from spironolactone that can cause potassium retention Monitor serum potassium weekly until stable, then every 6 months... 

POTASSIUM-SPARING DIURETICS TRILOSTANE Risk of hyperkalaemia Additive effect Monitor potassium levels regularly during co-administration... 

Diuretics NSAIDs cause sodium retention and reduce diuretic and antihypertensive efficacy risk of hyperkalaemia with potassium-sparing diuretics increased nephrotoxicity risk (with indomethacin, ketorolac). 

Interactions. Hyperkalaemia can result from use with potassium-sparing diuretics. Renal clearance of lithium is reduced and toxic concentrations of plasma lithium may follow. Severe hypotension can occur with diuretics (above), and with chlorpro-mazine, and possibly other phenothiazines. 

The combination of a potassium-sparing diuretic and ACE inhibitor can also cause severe hyponatraemia, more commonly indeed than life-threatening hyperkalaemia. 

There is a theoretical risk of hyperkalaemia with preparations containing potassium citrate. Such preparations should be avoided in patients taking potassium-sparing diuretics, spironolactone and angiotensin-converting enzyme inhibitors, and in patients with heart or kidney disease. 

Diuretics. Hypercalcaemia may develop in patients administered thiazide diuretics with either calcium or vitamin D supplements, leading to a need to monitor plasma or serum calcium levels. The concurrent use of potassium-sparing diuretics, and other potassium supplements or potassium-containing salt substitutes, could lead to serious hyperkalaemia. Hyperkalaemia is known to interfere with the absorption of vitamin B12. There is a need to warn patients and monitor serum potassium levels. The risk of hypokalaemia is minimal with low doses of thiazides, for example 5 mg of bendroflumethiazide. Hypokalaemia is a concern in patients receiving treatment with drugs such as digoxin, amiodarone, disopyramide or flecainide (drugs used to treat cardiac disorders). 

Potassium supplements + Potassium-sparing drugs (e.g. ACE inhibitors, Angiotensin II receptor antagonists. Potassium-sparing diuretics) Hyperkalaemia... 

---